Clinical trial
A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers
NCT02327000 is registered in ClinicalTrials.gov with GL Pharm Tech Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers
- Lead sponsor
- GL Pharm Tech Corporation
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2014
- Completion date
- October 31, 2014
- Enrollment
- 40 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
healthy